238 citations
,
November 2016 in “Journal of The American Academy of Dermatology” Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
2 citations
,
January 2025 in “Journal of Oncology Pharmacy Practice” Pembrolizumab can cause unusual eyelash growth, but it may still be worth continuing if cancer treatment is effective.
April 2025 in “The Journal of Dermatology” Janus kinase inhibitors may help treat cutaneous T-cell lymphoma, but more research is needed.
October 2021 in “Journal of Investigative Dermatology” Blocking IL-12 can help treat alopecia areata by preventing hair follicle immune issues.
9 citations
,
February 2011 in “Biologics: Targets & Therapy” Topical calcineurin inhibitors, especially 0.1% tacrolimus ointment, are effective and well-tolerated for treating cutaneous lupus erythematosus but require more research for standard treatment guidelines.
May 2023 in “International Journal of Trichology” Tofacitinib effectively treated severe hair loss in a patient who didn't respond to other treatments.
Ritlecitinib can reduce inflammation and help hair regrow in Alopecia Areata.
19 citations
,
November 2016 in “Dermatology and therapy” Stopping the medication infliximab and starting new treatments helped a woman's hair grow back and improved her scalp condition.
January 2024 in “Dermatologic Therapy” Tofacitinib effectively reduces hair loss in children with alopecia areata but may cause mild side effects and relapses.
May 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” Topical immunotherapy for alopecia areata may work by creating immune cell clusters in the skin.
June 2022 in “Frontiers in Immunology” Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.
15 citations
,
February 2024 in “Journal of Dermatological Treatment” Dupilumab may help treat alopecia areata without needing high IgE levels.
3 citations
,
September 2024 in “Dermatology and Therapy” Previous alopecia areata treatments do not affect the long-term effectiveness of ritlecitinib.
A TNFAIP3 gene mutation can cause unusual and varied symptoms of lupus and Sjogren's syndrome.
39 citations
,
November 2015 in “Pediatric Nephrology” Rituximab leads to longer remission and fewer side effects than cyclophosphamide.
March 2026 in “American Journal of Clinical Dermatology” 64 citations
,
May 2000 in “International Journal of Dermatology” Thalidomide improved lupus symptoms but caused nerve damage in some patients.
40 citations
,
September 2018 in “Journal of the American Academy of Dermatology” Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.
11 citations
,
September 1999 in “Journal of the European Academy of Dermatology and Venereology” Immunomodulatory therapies are effective for treating cutaneous lymphoma, particularly in early stages.
15 citations
,
January 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.
7 citations
,
July 2023 in “Immunotherapy” Ritlecitinib works well and is safe for treating alopecia areata.
December 2022 in “Pakistan Journal of Medical and Health Sciences” Tofacitinib effectively treats Alopecia Areata.
130 citations
,
February 2018 in “Journal of Investigative Dermatology” Tofacitinib may help treat severe hair loss, but more research is needed.
2 citations
,
January 2014 in “Journal of Cytology & Histology” Rapamycin and anti-EGFR antibody reduce LAM/TSC cell migration and blood vessel growth in the uterus.
2 citations
,
December 2021 in “Journal of Veterinary Medical Science” Lokivetmab reduced itching in a dog with skin lymphoma.
2 citations
,
November 2007 in “Clinics in dermatology” Tofacitinib may be an effective and safe treatment for adolescent alopecia areata.
1 citations
,
December 2012 in “Journal of dermatological science” Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.
February 2025 in “Journal of the European Academy of Dermatology and Venereology” Mogamulizumab can cause hair loss, often linked to a better treatment response.
May 2017 in “Journal of The American Academy of Dermatology” An intact skin barrier is crucial to prevent infection in cases of tether-induced tenosynovitis.
2 citations
,
January 2023 in “Anais Brasileiros de Dermatologia”